目的 探討復(fù)方蒲芩片聯(lián)合鹽酸莫西沙星氯化鈉注射液治療社區(qū)獲得性肺炎的臨床療效及對(duì)血清炎癥因子的影響。方法 回顧性分析2020年2月—2021年2月在平煤神馬集團(tuán)總醫(yī)院治療的102例社區(qū)獲得性肺炎患者的臨床資料，根據(jù)用藥的差別分為對(duì)照組和治療組，每組各51例。對(duì)照組靜脈滴注鹽酸莫西沙星氯化鈉注射液，0.4 g/次，1次/d；治療組在對(duì)照組基礎(chǔ)上口服復(fù)方蒲芩片，1 g/次，3次/d。兩組均經(jīng)14 d治療。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀改善時(shí)間，LCQ、CURB-65和中醫(yī)癥候積分，及血清C反應(yīng)蛋白（CRP）、白細(xì)胞介素-17（IL-17）、基質(zhì)金屬蛋白酶-9（MMP-9）、半乳糖凝聚素-3（Gal-3）和降鈣素原（PCT）水平。結(jié)果 治療后，治療組臨床有效率明顯高于對(duì)照組（98.04%vs 82.35%，P<0.05）。經(jīng)治療，治療組在臨床癥狀改善時(shí)間上均優(yōu)于對(duì)照組（P<0.05）。經(jīng)治療，兩組LCQ評(píng)分明顯升高，而CURB-65評(píng)分和中醫(yī)癥候積分明顯下降（P<0.05），且治療組評(píng)分明顯好于對(duì)照組（P<0.05）。經(jīng)治療，兩組血清CRP、IL-17、MMP-9、Gal-3、PCT水平明顯下降（P<0.05），且治療組降低更顯著（P<0.05）。結(jié)論 復(fù)方蒲芩片聯(lián)合鹽酸莫西沙星氯化鈉注射液治療社區(qū)獲得性肺炎可有效改善患者癥狀，降低機(jī)體炎癥反應(yīng)，提高患者生活質(zhì)量。

Objective To investigate the clinical efficacy of Compound Puqin Tablets combined with moxifloxacin in treatment of community-acquired pneumonia and its effect on serum inflammatory factors. Methods Retrospective analysis of the clinical data of 102 patients with community-acquired pneumonia in General Hospital of Pingmei Shenma Group from February 2020 to February 2021, and they were divided into control and treatment groups according to different treatments, and each group had 51 cases. Patients in the control group were iv administered with Moxifloxacin Hydrochloride and Sodium Chloride Injection, 0.4 g/time, once daily. Patients in the treatment group were po administered with Compound Puqin Tablets/time, 1 g/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, the improvement time of clinical symptoms, the scores of LCQ, CURB-65 and TCM syndrome, and the levels of serum CRP, IL-17, MMP-9, Gal-3 and PCT in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (98.04% vs 82.35%, P < 0.05). After treatment, the improvement time of clinical symptoms in the treatment group was better than that in the control group (P < 0.05). After treatment, the LCQ score were significantly increased, while the CURB-65 score and TCM syndrome score were significantly decreased in two groups (P < 0.05), and the scores in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the serum levels of CRP, IL-17, MMP-9, Gal-3 and PCT in two groups were significantly decreased (P < 0.05), especially in the treatment group (P < 0.05). Conclusion Compound Puqin Tablets combined with moxifloxacin in treatment of community-acquired pneumonia can effectively improve the symptoms of patients, reduce the inflammatory reaction, and improve the life treatment.

R974

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃聯(lián)合共建項(xiàng)目（LHGJ20200216）